Abstract
Cyclin-dependent kinase-2 (CDK2) is a member of protein kinase family. It plays an important role in regulating various events of eukaryotic cell division cycle. Accumulated evidences indicated that over expression of CDK2 should cause the abnormal regulation of cell-cycle, which would be directly associated with hyperproliferation in cancer cells. Therefore, CDK2 was regarded as a potentially therapeutic target for cancer therapy. Knowledge of crystallography and availability of X-ray crystal structure of CDK2 have enabled us to understand the mode of CDK2 inhibition, which facilitated the development of numerous CDK2 inhibitors. Some of the CDK2 inhibitors were investigated clinically for their potential as anti-cancer agents. In this review, we present the structure, functions and activation of CDK2 by cyclin binding with special focus on recent advances in the development of different classes of CDK2 inhibitors. We also summarize different strategies to achieve subtype specificity either by targeting a binding pocket other than ATP, i.e. allosteric ligand binding site or by natural protein inhibitors capable to disrupt CDK2-cyclin complexes. It is possible to develop pharmacologically relevant cytotoxic agents by specifically inhibiting CDK2 activity with lesser toxicity than traditional chemotherapeutic agents.
Keywords: Anti-cancer, anti-proliferative activity, CDK2, cell cycle, cyclin, kinase inhibitors.
Current Medicinal Chemistry
Title:Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
Volume: 22 Issue: 2
Author(s): Tahir Ali Chohan, Haiyan Qian, Youlu Pan and Jian-Zhong Chen
Affiliation:
Keywords: Anti-cancer, anti-proliferative activity, CDK2, cell cycle, cyclin, kinase inhibitors.
Abstract: Cyclin-dependent kinase-2 (CDK2) is a member of protein kinase family. It plays an important role in regulating various events of eukaryotic cell division cycle. Accumulated evidences indicated that over expression of CDK2 should cause the abnormal regulation of cell-cycle, which would be directly associated with hyperproliferation in cancer cells. Therefore, CDK2 was regarded as a potentially therapeutic target for cancer therapy. Knowledge of crystallography and availability of X-ray crystal structure of CDK2 have enabled us to understand the mode of CDK2 inhibition, which facilitated the development of numerous CDK2 inhibitors. Some of the CDK2 inhibitors were investigated clinically for their potential as anti-cancer agents. In this review, we present the structure, functions and activation of CDK2 by cyclin binding with special focus on recent advances in the development of different classes of CDK2 inhibitors. We also summarize different strategies to achieve subtype specificity either by targeting a binding pocket other than ATP, i.e. allosteric ligand binding site or by natural protein inhibitors capable to disrupt CDK2-cyclin complexes. It is possible to develop pharmacologically relevant cytotoxic agents by specifically inhibiting CDK2 activity with lesser toxicity than traditional chemotherapeutic agents.
Export Options
About this article
Cite this article as:
Chohan Ali Tahir, Qian Haiyan, Pan Youlu and Chen Jian-Zhong, Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents, Current Medicinal Chemistry 2015; 22 (2) . https://dx.doi.org/10.2174/0929867321666141106113633
DOI https://dx.doi.org/10.2174/0929867321666141106113633 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Current Pharmaceutical Design Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies
Current Gene Therapy Triazole and Oxadiazole Containing Natural Products: A Review
The Natural Products Journal Thiourea and Guanidine Derivatives as Antimalarial and Antimicrobial Agents<sup>§</sup>
Current Topics in Medicinal Chemistry Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Peptide-Drug Conjugate: A Novel Drug Design Approach
Current Medicinal Chemistry The Roles of the Unique Prolyl Isomerase Pin1 in Cancer-Related Viral and Bacterial Infections
Current Molecular Medicine The Biological Role of mTOR in the Pathogenesis of Solid Tumors: An Overview
Current Enzyme Inhibition Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population
Current Genomics Hypoxia Signaling and the Metastatic Phenotype
Current Molecular Medicine Targeting Tumor-Associated Antigens to the MHC Class I Presentation Pathway
Endocrine, Metabolic & Immune Disorders - Drug Targets In Vivo DNA Electrotransfer for Immunotherapy of Cancer and Neurodegenerative Diseases
Current Drug Metabolism Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Cancer Invasion and Metastasis: Discovering New Targets For Diagnosis and Therapeutics
Current Signal Transduction Therapy HIV Vaccine Efficacy and Immune Correlates of Risk
Current HIV Research CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer
Current Cancer Drug Targets Anticancer Immunotherapy in Combination with Proapoptotic Therapy
Current Cancer Drug Targets Mechanisms Used by Human Papillomaviruses to Escape the Host Immune Response
Current Cancer Drug Targets Using the Neurosphere Assay to Quantify Neural Stem Cells In Vivo
Current Pharmaceutical Biotechnology